Anthem Biosciences Limited (BOM:544449)
India · Delayed Price · Currency is INR 730.15
-20.30 (-2.71%)
At close: Aug 8, 2025
Marinus Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, Anthem Biosciences had annual revenue of 18.50B INR with 30.29% growth. Anthem Biosciences had revenue of 9.84B in the half year ending March 31, 2025.
Revenue
18.50B
Revenue Growth
+30.29%
P/S Ratio
22.14
Revenue / Employee
9.43M
Employees
1,825
Market Cap
409.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 18.50B | 4.30B | 30.29% |
| Mar 31, 2024 | 14.20B | 3.62B | 34.24% |
| Mar 31, 2023 | 10.58B | -1.83B | -14.74% |
| Mar 31, 2022 | 12.41B | 1.35B | 12.24% |
| Mar 31, 2021 | 11.05B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 639.28B |